PT  - JOURNAL ARTICLE
AU  - Feryal Alhamadani
AU  - Kristy Zhang
AU  - Rajvi Parikh
AU  - Hangyu Wu
AU  - Theodore P Rasmussen
AU  - Raman Bahal
AU  - Xiao-bo Zhong
AU  - Jose E. Manautou, PhD
TI  - <strong>Adverse Drug Reactions and Toxicity of the FDA-approved Antisense Oligonucleotide Drugs</strong>
AID  - 10.1124/dmd.121.000418
DP  - 2022 Jan 01
TA  - Drug Metabolism and Disposition
PG  - DMD-MR-2021-000418
4099  - http://dmd.aspetjournals.org/content/early/2022/02/27/dmd.121.000418.short
4100  - http://dmd.aspetjournals.org/content/early/2022/02/27/dmd.121.000418.full
AB  - The market for large molecule biological drugs has grown rapidly, including antisense oligonucleotide (ASO) drugs. ASO drugs work as single-stranded synthetic oligonucleotides that reduce production or alter functions of disease-causing proteins through various mechanisms, such as mRNA degradation, exon skipping, and ASO-protein interactions. After the first ASO drug Fomivirsen was approved in 1998, the US Food and Drug Administration has approved 10 ASO drugs to date. Although ASO drugs are efficacious in treating some diseases that are untargetable by small-molecule chemical drugs, concerns on adverse drug reactions (ADRs) and toxicity cannot be ignored. Illustrative of this, Mipomersen was recently taken off the market due to its hepatotoxicity risk. This paper reviews ADRs and toxicity from FDA drug labeling, preclinical studies, clinical trials, and post-marketing real-world studies on the ten FDA-approved ASO drugs, including Fomivirsen and Pegaptanib Mipomersen, Nusinersen, Inotersen, Defibrotide, Eteplirsen, Golodirsen, Viltolarsen, and Casimersen. Unique and common ADRs and toxicity for each ASO drug are summarized here. The risk of developing hepatotoxicity, kidney toxicity, and hypersensitivity reactions co-exists for multiple ASO drugs. Special precautions need to be in place when certain ASO drugs are administrated. Further discussion is extended on studying the mechanisms of ADRs and toxicity of these drugs, evaluating the existing physiological and pathological states of patients, optimizing the dose and route of administration, and formulating personalized treatment plans to improve the clinical utility of FDA-approved ASO drugs and discovery and development of new ASO drugs with reduced ADRs. Significance Statement The current review provides a comprehensive analysis of unique and common ADRs and the toxicity of FDA-approved ASO drugs. The information can help better manage the risk of severe hepatotoxicity, kidney toxicity, and hypersensitivity reactions in the usage of currently approved ASO drugs and the discovery and development of new and safer ASO drugs.